

**METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND
TREATMENT OF CARDIOVASCULAR AND TUMORIGENIC DISEASE USING
4941**

5

Abstract of the Disclosure

The present invention relates to methods and compositions for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, and endothelial cell disorders, such as disorders associated with aberrant endothelial cell growth, angiogenesis and/or vascularization, *e.g.*, tumorigenic disorders. Specifically, the present invention identifies GPCR 4941 genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention also identifies GPCR 4941 genes as differentially expressed in tumorigenic disease, *e.g.*, ovarian cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular and tumorigenic diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease and tumorigenic, and for monitoring the efficacy of compounds in clinical trials. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular and tumorigenic disease.